CNX Therapeutics has signed a license agreement with Klaria Pharma (Nasdaq First North: KLAR) to market and sell the migraine drug sumatriptan aginate in Europe.
The product is an innovative formulation which uses Klaria’s patented alginate film technology, designed for fast and reliable oral administration.
The agreement includes up-front and milestone payments totaling up to 2 million euros ($2.1 million), with royalties based on revenues. CNX plans to launch the treatment in Germany, Spain and Italy by late 2025, expanding to additional European markets in 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze